CAMBRIDGE, Mass.--(BUSINESS WIRE)--Platelet BioGenesis (PBG), the leader in the production of functional human platelets (PLTs+™) from stem cells and the development of platelet-based therapeutics, announced it has moved into brand new lab space in Cambridge, MA. Located next to MIT, the newly renovated property puts Platelet BioGenesis in the heart of the most dynamic biotech cluster in the world.
Platelet BioGenesis’ new space is located in Nest.Bio Labs, a unique incubator space that hosts a growing number of innovative early-stage life science companies.
"We are thrilled to have Platelet BioGenesis as one of our founding tenants,” commented James Weis, CEO of Nest.Bio Labs. “As pioneers in cell therapy, this company is a standout in our carefully cultivated community of trailblazing ventures.”
The new lab space, located at 325 Vassar Street, will accommodate PBG’s aggressive growth, which has seen the startup more than double in size in less than a year. The 14,000-square-foot facility includes more than 50 oversized wet lab benches as well as a state-of-the-art tissue culture and microscopy suites to support R&D operations.
“Platelet BioGenesis’ move to Cambridge will accelerate our continued growth as we scale our novel method of generating disease-free, GMP-compliant, donor-independent, functional human platelets,” said Ryan Chappell, lab manager of Platelet BioGenesis. “We anticipate hiring additional scientific and administrative personnel as we advance to the clinic.”
Added Jonathan Thon, Ph.D., PBG co-founder and CEO, “Surrounding ourselves with other growing life science companies in the Nest.Bio incubator adds to the excitement of our rapid progress. Platelet BioGenesis’ goal is to alleviate the chronic shortage of platelets for transfusion to cancer patients, those undergoing surgery, and others in need of these life-saving cells.”
About Platelet BioGenesis
Platelet BioGenesis is a
venture-backed, development stage biotech company creating the world’s
first donor-independent source of platelets to address the chronic
platelet shortage that affects patients worldwide. The company has
developed and patented a scalable cGMP-compliant process to generate
platelets from human induced pluripotent stem cells. Based in Cambridge,
Mass., Platelet BioGenesis is also developing designer platelets
(PLTs+™), a new class of therapeutics to treat cancer and other
life-threatening diseases. The company was spun out of Harvard
University and has received funding from the Massachusetts
Life Sciences Center, the National
Institutes of Health and the U.S.
Department of Defense. Learn more at www.plateletbiogenesis.com
and follow us on Twitter @plateletbiogen.
About Nest.Bio Labs
Launched in partnership with pioneering
entrepreneurs and investors, Nest.Bio
Labs is a shared community designed specifically to hatch
revolutionary biotechnology ventures. Nest.Bio Lab’s 14,000-square-foot
facility includes turnkey laboratory services, state-of-the-art tissue
culture and microscopy suites, and extensive core equipment and
instrumentation. Located next to MIT in the international biotechnology
hub of Cambridge, Massachusetts, Nest.Bio Labs brings together a
carefully selected group of tenants and partners to create a complete
life sciences incubation ecosystem.
